452 related articles for article (PubMed ID: 29472362)
1. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C; Fautrel B; Rech J; Spertini F; Feist E; Kötter I; Hachulla E; Morel J; Schaeverbeke T; Hamidou MA; Martin T; Hellmich B; Lamprecht P; Schulze-Koops H; Courvoisier DS; Sleight A; Schiffrin EJ
Ann Rheum Dis; 2018 Jun; 77(6):840-847. PubMed ID: 29472362
[TBL] [Abstract][Full Text] [Related]
2. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
Kiltz U; Kiefer D; Braun J; Schiffrin EJ; Girard-Guyonvarc'h C; Gabay C
Ann Rheum Dis; 2020 Jan; 79(1):e10. PubMed ID: 30352887
[No Abstract] [Full Text] [Related]
3. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences.
Kraetsch HG; Antoni C; Kalden JR; Manger B
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii55-7. PubMed ID: 11890655
[TBL] [Abstract][Full Text] [Related]
5. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
6. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-18: a biomarker with therapeutic potential in adult-onset Still's disease.
Chen PK; Wey SJ; Chen DY
Expert Rev Clin Immunol; 2022 Aug; 18(8):823-833. PubMed ID: 35771972
[TBL] [Abstract][Full Text] [Related]
8. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Kedor C; Listing J; Zernicke J; Weiß A; Behrens F; Blank N; Henes JC; Kekow J; Rubbert-Roth A; Schulze-Koops H; Seipelt E; Specker C; Feist E
Ann Rheum Dis; 2020 Aug; 79(8):1090-1097. PubMed ID: 32404342
[TBL] [Abstract][Full Text] [Related]
10. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options and safety considerations when treating adult-onset Still's disease.
Cavalli G; Farina N; Campochiaro C; Baldissera E; Dagna L
Expert Opin Drug Saf; 2020 Dec; 19(12):1549-1558. PubMed ID: 33078630
[TBL] [Abstract][Full Text] [Related]
12. Etanercept in the treatment of adult patients with Still's disease.
Husni ME; Maier AL; Mease PJ; Overman SS; Fraser P; Gravallese EM; Weinblatt ME
Arthritis Rheum; 2002 May; 46(5):1171-6. PubMed ID: 12115220
[TBL] [Abstract][Full Text] [Related]
13. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review on adult onset Still's disease.
Giacomelli R; Ruscitti P; Shoenfeld Y
J Autoimmun; 2018 Sep; 93():24-36. PubMed ID: 30077425
[TBL] [Abstract][Full Text] [Related]
15. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?
Dall'Ara F; Frassi M; Tincani A; Airò P
Clin Rheumatol; 2016 Aug; 35(8):2117-2123. PubMed ID: 26758435
[TBL] [Abstract][Full Text] [Related]
18. Adult-onset Still's disease: clinical, serological and therapeutic considerations.
Iliou C; Papagoras C; Tsifetaki N; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2013; 31(1):47-52. PubMed ID: 23010097
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
[TBL] [Abstract][Full Text] [Related]
20. Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
Kacar M; Fitton J; Gough AK; Buch MH; McGonagle DG; Savic S
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
